CN104906044A - 一种癸氧喹酯纳米制剂及其制备方法与应用 - Google Patents
一种癸氧喹酯纳米制剂及其制备方法与应用 Download PDFInfo
- Publication number
- CN104906044A CN104906044A CN201510266332.9A CN201510266332A CN104906044A CN 104906044 A CN104906044 A CN 104906044A CN 201510266332 A CN201510266332 A CN 201510266332A CN 104906044 A CN104906044 A CN 104906044A
- Authority
- CN
- China
- Prior art keywords
- deccox
- nanometer formulation
- malaria
- preparation
- decoquinate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JHAYEQICABJSTP-UHFFFAOYSA-N decoquinate Chemical compound N1C=C(C(=O)OCC)C(=O)C2=C1C=C(OCC)C(OCCCCCCCCCC)=C2 JHAYEQICABJSTP-UHFFFAOYSA-N 0.000 title claims abstract description 205
- 238000002360 preparation method Methods 0.000 title claims abstract description 65
- 238000000034 method Methods 0.000 title claims abstract description 42
- 229960001878 decoquinate Drugs 0.000 title abstract description 16
- 239000004094 surface-active agent Substances 0.000 claims abstract description 61
- 201000004792 malaria Diseases 0.000 claims abstract description 35
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims description 95
- 238000009472 formulation Methods 0.000 claims description 81
- 239000002245 particle Substances 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 20
- 229920002521 macromolecule Polymers 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000006185 dispersion Substances 0.000 claims description 15
- 239000007962 solid dispersion Substances 0.000 claims description 14
- 239000003960 organic solvent Substances 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- 235000012000 cholesterol Nutrition 0.000 claims description 10
- 229920000136 polysorbate Polymers 0.000 claims description 10
- 235000002378 plant sterols Nutrition 0.000 claims description 9
- 229950008882 polysorbate Drugs 0.000 claims description 9
- 238000002604 ultrasonography Methods 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 108010000912 Egg Proteins Proteins 0.000 claims description 6
- 102000002322 Egg Proteins Human genes 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 235000013345 egg yolk Nutrition 0.000 claims description 6
- 210000002969 egg yolk Anatomy 0.000 claims description 6
- 150000003904 phospholipids Chemical class 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 5
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 238000000265 homogenisation Methods 0.000 claims description 5
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 4
- 229920001983 poloxamer Polymers 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 claims description 2
- 206010035501 Plasmodium malariae infection Diseases 0.000 claims description 2
- 201000006537 Plasmodium malariae malaria Diseases 0.000 claims description 2
- 206010035502 Plasmodium ovale infection Diseases 0.000 claims description 2
- 201000009705 Plasmodium ovale malaria Diseases 0.000 claims description 2
- 206010035503 Plasmodium vivax infection Diseases 0.000 claims description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 230000000857 drug effect Effects 0.000 abstract description 20
- 238000004090 dissolution Methods 0.000 abstract description 13
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 37
- 238000012360 testing method Methods 0.000 description 26
- 241000224016 Plasmodium Species 0.000 description 20
- 210000003743 erythrocyte Anatomy 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 239000003430 antimalarial agent Substances 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 12
- 230000000078 anti-malarial effect Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- 229960003677 chloroquine Drugs 0.000 description 11
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 11
- 239000008346 aqueous phase Substances 0.000 description 9
- 229930191701 arteannuin Natural products 0.000 description 9
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 9
- 229960004191 artemisinin Drugs 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 241000223960 Plasmodium falciparum Species 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000007791 liquid phase Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- -1 oxy radical Chemical class 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010003399 Arthropod bite Diseases 0.000 description 4
- ZDPIZLCVJAAHHR-UHFFFAOYSA-N Clopidol Chemical compound CC1=NC(C)=C(Cl)C(O)=C1Cl ZDPIZLCVJAAHHR-UHFFFAOYSA-N 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 4
- 229930182566 Gentamicin Natural products 0.000 description 4
- 241000224017 Plasmodium berghei Species 0.000 description 4
- 241000594182 Sarcophaga sigma Species 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000002736 nonionic surfactant Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 208000003495 Coccidiosis Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010023076 Isosporiasis Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 description 3
- 229960003159 atovaquone Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000031891 intestinal absorption Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical class N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000000273 veterinary drug Substances 0.000 description 3
- DAUXLKFOFAZKPU-UHFFFAOYSA-N 3,7-dihydropurin-6-one Chemical compound OC1=NC=NC2=C1NC=N2.O=C1NC=NC2=C1NC=N2 DAUXLKFOFAZKPU-UHFFFAOYSA-N 0.000 description 2
- 101000656751 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S24e Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001165 anti-coccidial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000013022 formulation composition Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229960005179 primaquine Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- NWNOWCGAHDFNFJ-RUCXOUQFSA-N (2s)-2,5-bis(azanyl)-5-oxidanylidene-pentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(N)=O.OC(=O)[C@@H](N)CCC(N)=O NWNOWCGAHDFNFJ-RUCXOUQFSA-N 0.000 description 1
- IOTAOYHKWICOBK-UHFFFAOYSA-N 1-[amino-(4-chloroanilino)methylidene]-2-propan-2-ylguanidine;3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione;hydrochloride Chemical compound Cl.CC(C)N=C(N)\N=C(/N)NC1=CC=C(Cl)C=C1.O=C1C(=O)C2=CC=CC=C2C(O)=C1C(CC1)CCC1C1=CC=C(Cl)C=C1 IOTAOYHKWICOBK-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100025287 Cytochrome b Human genes 0.000 description 1
- 108010075028 Cytochromes b Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000224021 Plasmodium berghei ANKA Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Chemical group 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101001000212 Rattus norvegicus Decorin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- FVJZSBGHRPJMMA-DHPKCYQYSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-octadecanoyloxypropyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-DHPKCYQYSA-N 0.000 description 1
- 239000000980 acid dye Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001203 anti-plasmodial effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940114027 atovaquone / proguanil Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000004064 cosurfactant Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- FVJZSBGHRPJMMA-UHFFFAOYSA-N distearoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- XDDAORKBJWWYJS-UHFFFAOYSA-N glyphosate Chemical compound OC(=O)CNCP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003936 merozoite Anatomy 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- PMZDQRJGMBOQBF-UHFFFAOYSA-N quinolin-4-ol Chemical compound C1=CC=C2C(O)=CC=NC2=C1 PMZDQRJGMBOQBF-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102220069615 rs373911322 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000007785 strong electrolyte Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510266332.9A CN104906044B (zh) | 2015-05-22 | 2015-05-22 | 一种癸氧喹酯纳米制剂及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510266332.9A CN104906044B (zh) | 2015-05-22 | 2015-05-22 | 一种癸氧喹酯纳米制剂及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104906044A true CN104906044A (zh) | 2015-09-16 |
CN104906044B CN104906044B (zh) | 2019-05-07 |
Family
ID=54075777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510266332.9A Active CN104906044B (zh) | 2015-05-22 | 2015-05-22 | 一种癸氧喹酯纳米制剂及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104906044B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107427504A (zh) * | 2015-12-08 | 2017-12-01 | 广州中科蓝华生物科技有限公司 | 癸氧喹酯固体分散体、其制备方法和用途 |
CN109496152A (zh) * | 2018-05-17 | 2019-03-19 | 广州蓝亮医药科技有限公司 | 癸氧喹酯组合物的肌肉内库存及其预防和治疗的方法 |
WO2020140197A1 (en) * | 2019-01-02 | 2020-07-09 | Bluelight Pharmatech Co., Ltd | Nanoparticle formulations of decoquinate in the form of solid solution |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110585134B (zh) * | 2019-10-18 | 2022-11-29 | 中科蓝华(广州)生物医药技术有限公司 | 一种癸氧喹酯脂质体及其制备方法和应用 |
CN110898096A (zh) * | 2019-11-22 | 2020-03-24 | 佛山市正典生物技术有限公司 | 一种癸氧喹酯微囊及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1333679A (zh) * | 1998-11-20 | 2002-01-30 | Rtp药品公司 | 可分散的磷脂稳定的微粒 |
CN101095684A (zh) * | 2006-06-28 | 2008-01-02 | 黑龙江大学 | 熊果酸磷脂复合物及其制备方法和应用 |
CN101564376A (zh) * | 2009-04-10 | 2009-10-28 | 烟台绿叶动物保健品有限公司 | 癸氧喹酯固体分散体及其制备 |
CN102525919A (zh) * | 2011-11-28 | 2012-07-04 | 河南牧翔动物药业有限公司 | 一种癸氧喹酯纳米乳抗球虫药物及其制备方法 |
CN104434807A (zh) * | 2014-11-10 | 2015-03-25 | 上海交通大学 | 紫杉醇及其同系物固体分散体纳米粒及其制备方法 |
-
2015
- 2015-05-22 CN CN201510266332.9A patent/CN104906044B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1333679A (zh) * | 1998-11-20 | 2002-01-30 | Rtp药品公司 | 可分散的磷脂稳定的微粒 |
CN101095684A (zh) * | 2006-06-28 | 2008-01-02 | 黑龙江大学 | 熊果酸磷脂复合物及其制备方法和应用 |
CN101564376A (zh) * | 2009-04-10 | 2009-10-28 | 烟台绿叶动物保健品有限公司 | 癸氧喹酯固体分散体及其制备 |
CN102525919A (zh) * | 2011-11-28 | 2012-07-04 | 河南牧翔动物药业有限公司 | 一种癸氧喹酯纳米乳抗球虫药物及其制备方法 |
CN104434807A (zh) * | 2014-11-10 | 2015-03-25 | 上海交通大学 | 紫杉醇及其同系物固体分散体纳米粒及其制备方法 |
Non-Patent Citations (2)
Title |
---|
HONGXING WANG等: "Nanoparticle formulations of decoquinate increase antimalarial efficacy against liver stage Plasmodium infections in mice", 《NANOMEDICINE:NANOTECHNOLOGY,BIOLOGY AND MEDICINE》 * |
龚显峰等: "葛根素固体分散体的制备及大鼠体内生物利用度研究", 《黑龙江医药》 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107427504A (zh) * | 2015-12-08 | 2017-12-01 | 广州中科蓝华生物科技有限公司 | 癸氧喹酯固体分散体、其制备方法和用途 |
CN107427504B (zh) * | 2015-12-08 | 2020-10-09 | 广州蓝亮医药科技有限公司 | 癸氧喹酯固体分散体、其制备方法和用途 |
CN109496152A (zh) * | 2018-05-17 | 2019-03-19 | 广州蓝亮医药科技有限公司 | 癸氧喹酯组合物的肌肉内库存及其预防和治疗的方法 |
WO2019218305A1 (en) * | 2018-05-17 | 2019-11-21 | Bluelight Pharmatech Co., Ltd | Intramuscular depot of decoquinate compositions and method of prophylaxis and treatment thereof |
CN109496152B (zh) * | 2018-05-17 | 2021-06-18 | 广州蓝亮医药科技有限公司 | 癸氧喹酯组合物的肌肉内库存及其预防和治疗的方法 |
US11246836B2 (en) | 2018-05-17 | 2022-02-15 | Bluelight Pharmatech Co., Ltd. | Intramuscular depot of decoquinate compositions and method of prophylaxis and treatment thereof |
WO2020140197A1 (en) * | 2019-01-02 | 2020-07-09 | Bluelight Pharmatech Co., Ltd | Nanoparticle formulations of decoquinate in the form of solid solution |
CN111698990A (zh) * | 2019-01-02 | 2020-09-22 | 广州蓝亮医药科技有限公司 | 固态溶液形式的癸氧喹酯纳米粒子制剂 |
US11602532B2 (en) | 2019-01-02 | 2023-03-14 | Cas Lamvac (Guangzhou) Biomedical Technology Co., Ltd. | Nanoparticle formulations of decoquinate in the form of solid solution |
Also Published As
Publication number | Publication date |
---|---|
CN104906044B (zh) | 2019-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104906044A (zh) | 一种癸氧喹酯纳米制剂及其制备方法与应用 | |
Hasan et al. | Formulation and evaluation of metformin hydrochloride-loaded niosomes as controlled release drug delivery system | |
Yen et al. | Nanoparticles formulation of Cuscuta chinensis prevents acetaminophen-induced hepatotoxicity in rats | |
Scalise et al. | Promising efficacy of benznidazole nanoparticles in acute Trypanosoma cruzi murine model: in-vitro and in-vivo studies | |
CN101658494B (zh) | 一种石杉碱甲固体脂质纳米粒及其制备方法 | |
KR20000064762A (ko) | 프로포폴미세비말제제 | |
CN103357016B (zh) | 治疗耐药性结核病的药物组合物 | |
Wang et al. | Enhanced antimalarial efficacy obtained by targeted delivery of artemisinin in heparin-coated magnetic hollow mesoporous nanoparticles | |
Ali et al. | Lipoparticles for synergistic chemo-photodynamic therapy to ovarian carcinoma cells: in vitro and in vivo assessments | |
CN102458378A (zh) | 用于递送活性化合物的胶态系统的制备方法 | |
CN106852930A (zh) | 一种伊维菌素类药物口服固体制剂的制备方法 | |
CN103405385A (zh) | 一种替莫唑胺静脉注射脂肪乳及其制备方法 | |
Luo et al. | Rivaroxaban-loaded SLNs with treatment potential of deep vein thrombosis: in-vitro, in-vivo, and toxicity evaluation | |
US20240108580A1 (en) | Decoquinate liposome, preparation method therefor and use thereof | |
Wasan et al. | Assessing the safety, tolerability, pharmacokinetics, and biodistribution of novel oral formulations of amphotericin b following single-and multiple-dose administration to Beagle dogs | |
BRPI0517241B1 (pt) | composição farmacêutica, e, método para preparar a mesma | |
EP1547615B1 (en) | Remedy | |
CN101411686A (zh) | 克拉霉素亚微乳注射液及其制备方法 | |
CN102319302B (zh) | 赤芍总苷自微乳化软胶囊及其制备方法 | |
CN101879169B (zh) | 一种治疗血管相关疾病的复方制剂及其制备方法 | |
CN102247320B (zh) | 一种依托泊苷长循环乳剂及其制备方法 | |
CN109481692A (zh) | 一种青蒿琥酯肝素衍生物及其药物组合物和应用 | |
WO2019194692A1 (en) | Nanocapsule with liquid oil core, its preparation method and application | |
JAIN et al. | FORMULATION AND CHARACTERIZATION OF GDL-BASED ARTESUNATE SOLID LIPID NANOPARTICLE | |
CN102631326A (zh) | 一种注射用缓释微球及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180226 Address after: 510530 Guangzhou, Guangzhou City, Guangdong Province, new Guangzhou knowledge city, nine Buddhas, Jianshe Road, No. 397, room 115 Applicant after: Guangzhou blue bright Pharmaceutical Technology Co., Ltd. Address before: Moon Road, Science City high tech Industrial Development Zone of Guangzhou City, Guangdong province 510670 No. 3 Guangzhou international business incubator F District No. F413 room Applicant before: GUANGZHOU CAS LAMVAC BIOTECH CO., LTD. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220330 Address after: 510555 room 393, No. 115, jiufo Jianshe Road, Zhongxin Guangzhou Knowledge City, Guangzhou, Guangdong Patentee after: Zhongke Lanhua (Guangzhou) Biomedical Technology Co.,Ltd. Address before: 510530 room 397, No. 115, jiufo Jianshe Road, Zhongxin Guangzhou Knowledge City, Guangzhou, Guangdong Patentee before: BLUELIGHT PHARMATECH Co.,Ltd. |
|
TR01 | Transfer of patent right |